Joseph R Garlich
Overview
Explore the profile of Joseph R Garlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joshi S, Liu K, Zulcic M, Singh A, Skola D, Glass C, et al.
Mol Cancer Ther
. 2020 Jan;
19(3):755-764.
PMID: 31974273
Macrophages (MΦ) play a critical role in tumor growth, immunosuppression, and inhibition of adaptive immune responses in cancer. Hence, targeting signaling pathways in MΦs that promote tumor immunosuppression will provide...
2.
Joshi S, Singh A, Liu K, Pham T, Zulcic M, Skola D, et al.
Mol Cancer Ther
. 2019 Apr;
18(6):1036-1044.
PMID: 31018997
Macrophages (MΘs) are key immune infiltrates in solid tumors and serve as major drivers behind tumor growth, immune suppression, and inhibition of adaptive immune responses in the tumor microenvironment (TME)....
3.
Erdreich-Epstein A, Singh A, Joshi S, Vega F, Guo P, Xu J, et al.
Oncotarget
. 2017 Sep;
8(32):52193-52210.
PMID: 28881723
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Our previous studies showed that the angiogenic integrin αβ was increased in high-risk metastatic (stage 4) NB compared with...
4.
Andrews F, Singh A, Joshi S, Smith C, Morales G, Garlich J, et al.
Proc Natl Acad Sci U S A
. 2017 Feb;
114(7):E1072-E1080.
PMID: 28137841
is a major cancer driver but is documented to be a difficult therapeutic target itself. Here, we report on the biological activity, the structural basis, and therapeutic effects of the...
5.
Singh A, Joshi S, Burgoyne A, Sicklick J, Ikeda S, Kono Y, et al.
Mol Cancer Ther
. 2016 Aug;
15(11):2553-2562.
PMID: 27496136
Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug clinically approved for patients with advanced HCC, blocks the Ras/Raf/MAPK pathway...
6.
Singh A, Joshi S, Zulcic M, Alcaraz M, Garlich J, Morales G, et al.
PLoS One
. 2016 Mar;
11(3):e0150836.
PMID: 26938241
Sonic hedgehog (SHH) medulloblastoma (MB) subtype is driven by a proliferative CD15+ tumor propagating cell (TPC), also considered in the literature as a putative cancer stem cell (CSC). Despite considerable...
7.
Morales G, Garlich J, Su J, Peng X, Newblom J, Weber K, et al.
J Med Chem
. 2013 Feb;
56(5):1922-39.
PMID: 23410005
Dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway in a wide range of tumors has made PI3K a consensus target to inhibit as illustrated by more than 15 inhibitors now in clinical...
8.
De P, Dey N, Terakedis B, Bergsagel P, Li Z, Mahadevan D, et al.
Cancer Chemother Pharmacol
. 2013 Jan;
71(4):867-81.
PMID: 23355037
Purpose: Multiple reports point to an important role for the phosphoinositide-3 kinase (PI3K) and AKT signaling pathways in tumor survival and chemoresistance in multiple myeloma (MM). The goals of our...
9.
Garlich J, De P, Dey N, Su J, Peng X, Miller A, et al.
Cancer Res
. 2008 Jan;
68(1):206-15.
PMID: 18172313
PTEN and the pan phosphoinositide 3-kinase (PI3K) inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1 benzopyran-4-one (LY294002) exert significant control over tumor-induced angiogenesis and tumor growth in vivo. The LY294002 compound is not a viable drug...